Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.63 |
| ▸ | HTR1A | P08908 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3850852 | 0.91 | HTR6 (0.72) | HTR6KCNH2 | |
| SCHEMBL3858999 | 0.84 | HTR6 (0.54) | HTR6HTR1ADRD2HTR2AKCNH2 | |
| SCHEMBL3853287 | 0.82 | HTR6 (0.52) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3853722 | 0.81 | HTR6 (0.55) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3854522 | 0.81 | HTR6 (0.55) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3857007 | 0.80 | HTR6 (0.44) | HTR6HTR1AIDO1POLBGRIN1 | |
| SCHEMBL1136537 | 0.77 | HTR6 (1.00) | HTR6HTR1ADRD2KCNH2SLC6A2 | |
| Hydrochloric Acid SCHEMBL3855676 | 0.76 | HTR6 (0.97) | HTR6HTR1ADRD2KCNH2SLC6A2 | |
| SCHEMBL3857104 | 0.74 | HTR6 (0.47) | HTR6HTR1AIDO1POLBGRIN1 | |
| SCHEMBL3854532 | 0.73 | GRIN1 (0.49) | HTR6GRIN1GRIN2BSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | claimed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582760-B2 | 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. | ROCHE PALO ALTO LLC (US) | 2009-09-01 | — | — | US | disclosed |
| WO-2007006677-A1 | BENZIMIDAZOLE DERIVATIVES AS 5-HT6,5-HT24 | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015744-A1 | Benzimidazolone and dihydroindolone derivatives and uses thereof | RECQL, AR, DHX35 | HTR6 1077/4885HTR1A 393/4885DRD2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.